This section of the website is intended for Healthcare Professionals

Development pipeline

Find out where our cannabinoid products are in development along with their regulatory status and specialist therapy areas in Europe.

CBDV (GWP42006)

This is a homologue of cannabidiol currently being developed for the treatment of epilepsy and autism spectrum disorders. It has a very slightly different chemical structure to the original molecule but has been shown to posses similar properties. It is also a non-psychoactive cannabinoid. It is currently in the initial stages of development, but has so far shown promising results.

Pipeline key

Pre-clinic
Phase 1
Phase 2
Phase 3

Other

In addition, we have a number of other products at various stages in the development pipeline. These include GWP42003 IV for Neonatal Hypoxic-Ischemic Encephalopathy, GWP42002/GWP42003 for Glioblastoma, and GWP42003 for Schizophrenia.